LifeBTK Trial: Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease
Description
In this episode of Audible Bleeding, Jamila, Anh, and Naveed discuss the LifeBTK Trial with Principal Investigator Dr. Brian DeRubertis, where we discuss the new Abbott Esprit everolimus-eluting resorbable scaffold for the below-knee popliteal space.
Guest:
Dr. DeRubertis, is the Principal Investigator of the LIFE-BTK trial. He is the Chief of the Division of Vascular & Endovascular Surgery at New York-Presbyterian and Weill Cornell Medicine in New York City.
Audible Bleeding Team
Dr. Jamila Hedhliis a general surgery resident at the University of Illinois.
Anh Dang, (@QuynhAnh_Dang), is a fourth year medical student at the University of Pennsylvania.
Dr. Naveed A. Rahman, (@naveedrahmanmd), is a Vascular Surgery Fellow at the University of Maryland.
References:
-
Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease (LIFE-BTK).
-
Advances in Endovascular Treatment of CLTI: Insights From the LIFE-BTK Trial.
-
The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes.
Follow us @audiblebleeding
Learn more about us at https://www.audiblebleeding.com/about-1/ and provide us with your feedback with our listener survey.
United States
